
Target action date for FDA decision is due on 15 November

Review begins for potential schizophrenia and bipolar I disorder drug

Shares rocketed following the announcement

Value leaps to more than $1bn following mid-stage trial results

Follows company making job cuts in September as part of cost-saving efforts

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

Early stage studies look positive for schizophrenia drug
Collaborates with Mindstrong Health on mental health research

But will keep testing the candidate in schizophrenia

Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia